Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Supernus Pharmaceuticals, Inc. (SUPN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Supernus is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases, and its filings offer detailed insight into its commercial portfolio, collaborations, and pipeline.
Supernus’s current reports on Form 8-K cover a range of material events. These include announcements of quarterly financial results, where the company reports total revenues, net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products, as well as royalty, licensing and other revenues and collaboration revenue from ZURZUVAE. Filings also describe non-GAAP measures like adjusted operating earnings and revenues excluding certain legacy products.
Other 8-K filings document corporate transactions, notably the acquisition of Sage Therapeutics, Inc. Supernus details the merger structure, consideration, contingent value rights (CVRs) tied to ZURZUVAE milestones, and the integration of Sage as a wholly owned subsidiary. These filings also outline the collaboration economics with Biogen Inc. related to ZURZUVAE, an oral treatment for postpartum depression.
Additional disclosures address operational updates, such as supply constraints for ONAPGO due to stronger than expected demand and the company’s decision to prioritize existing patients while working to rebuild inventory. Filings also announce upcoming earnings release dates and conference calls, reinforcing the company’s regular reporting cadence.
On Stock Titan, investors can use AI-powered tools to read concise summaries of Supernus’s 8-Ks and other SEC documents, quickly understand key points about CNS product performance, collaboration revenue, acquisitions, and pipeline developments, and identify items such as contingent value rights or other material agreements without manually parsing lengthy filings.
SUPERNUS PHARMACEUTICALS, INC. senior vice president Frank Mottola reported a mix of equity award activity and related share dispositions. On February 24, 2026, several restricted stock unit (RSU) awards vested, and RSUs totaling 1,125, 750 and 1,250 units were disposed of back to the company. Each RSU represents the right to receive one share of Supernus common stock upon vesting.
On the same date, Mottola received three common stock grants of 1,125, 750 and 1,250 shares at no cost, while 603, 368 and 670 common shares were delivered back to the company at prices of $51.35 and $50.86 to satisfy tax withholding obligations tied to the RSU vesting. The RSU awards vest in four equal annual installments beginning on February 19, 2026, February 22, 2023 and February 22, 2025, as applicable.
SUPERNUS PHARMACEUTICALS SVP and Chief Medical Officer Jonathan Rubin reported multiple equity compensation events. On February 24, 2026, restricted stock units were disposed back to the company as they vested, and corresponding shares of common stock were acquired. Some of these new shares were withheld by the company to cover tax obligations. The RSUs each convert into one share of common stock and vest in four equal annual installments beginning on February 19, 2026, February 22, 2023, and February 22, 2025, depending on the grant.
SUPERNUS PHARMACEUTICALS, INC. director Georges Gemayel reported a mix of equity award activity and option exercises. On February 24, 2026, 4,475 restricted stock units were disposed of back to the issuer, while a matching 4,475 shares of common stock were acquired as a grant at no cost, bringing direct holdings in common stock to 38,159 shares.
On February 23, 2026, he exercised a director stock option for 15,000 shares of common stock at an exercise price of $12.98 per share, increasing his direct common stock ownership to 33,684 shares immediately after that exercise. Footnotes state each restricted stock unit represents one share of common stock and will settle in stock upon vesting on February 19, 2026.
Supernus Pharmaceuticals updated compensation for key executives following its annual review. The Board increased CEO Jack Khattar’s annual base salary from $1,036,000 to $1,067,100, awarded a 2025 cash bonus of $846,930, and granted options for 341,610 shares plus 204,966 performance share units that vest based on performance goals.
Other senior executives received base salary increases, 2025 cash bonuses, and equity awards combining stock options, restricted stock units, and performance share units. Option and RSU grants vest in equal annual installments over four years at an exercise price of $50.20 per share, while PSU vesting depends on performance as certified by the Compensation Committee.
Supernus Pharmaceuticals reported record revenue for both the fourth quarter and full year 2025 but moved from profit to loss due mainly to acquisition-related costs. Total revenues reached $211.6 million in Q4 2025, up 21% year over year, and $719.0 million for 2025, up 9%.
Growth products were the main driver, with combined revenues of $161.3 million in Q4 and $521.8 million for 2025, rising 45% and 40%. Newer assets performed strongly: ONAPGO generated $8.9 million in Q4 sales after its April launch and ZURZUVAE collaboration revenue was $32.8 million. However, 2025 GAAP operating results swung to a $62.3 million loss and net loss of $38.6 million, largely reflecting approximately $72.9 million in costs tied to the Sage Therapeutics acquisition and higher amortization and contingent consideration. Adjusted operating earnings were $158.7 million. Cash, cash equivalents and marketable securities were $308.7 million at year-end, after funding the Sage deal. For 2026, Supernus guides to total revenues of $840–$870 million, GAAP operating earnings of $0–$30 million, and adjusted operating earnings of $140–$170 million.
SUPERNUS PHARMACEUTICALS, INC. director Bethany Sensenig reported a set of stock transactions involving restricted stock units and common shares of SUPN. On February 19, 2026, she exercised 4,475 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share as the units vested.
That same day, she conducted open-market sales of common stock in two blocks: 1,217 shares at a weighted average price of $50.31 (with individual trades between $49.83 and $50.71) and 3,258 shares at a weighted average price of $51.27 (with trades between $50.98 and $51.56). These sales, totaling 4,475 shares, were made under a Rule 10b5-1 trading plan adopted on May 15, 2025, and left her with 0 shares of common stock directly owned after the reported transactions.
Supernus Pharmaceuticals reported that Senior Vice-President & CFO Timothy C. Dec received new equity awards. He was granted employee stock options for 17,500 shares at a price of $0.00 per share, which vest in four equal annual installments beginning on February 18, 2027. He also received 3,000 restricted stock units, each representing one share of common stock, vesting in four equal annual installments starting on the same date and settled in common stock upon vesting. Following these awards, he directly holds 1,638 shares of common stock, including an aggregate of 392 shares acquired through the company’s Employee Stock Purchase Plan.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief scientific officer Padmanabh P. Bhatt reported equity awards on February 18, 2026. He received an option to buy 13,500 shares of common stock and 3,000 restricted stock units, both granted at $0.00 per share as compensation.
The option and RSUs vest in four equal annual installments beginning on February 18, 2027. Following these awards, Bhatt directly holds 14,900 shares of common stock, which includes 392 shares acquired through the company’s employee stock purchase plan, along with the new option and RSU positions.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief medical officer Jonathan Rubin received new equity awards. On February 18, 2026, he was granted an employee stock option for 13,500 shares and 3,000 restricted stock units, both at no exercise cost per the filing.
The option vests in four equal annual installments starting February 18, 2027. Each restricted stock unit converts into one share of common stock and also vests in four equal annual installments beginning on that date. Following these awards, Rubin directly holds 11,284 shares of common stock, including 269 acquired through the employee stock purchase plan.
SUPERNUS PHARMACEUTICALS, INC. reported that SVP and Chief Technical Operations Officer Frank Mottola received new equity awards. He was granted employee stock options for 13,500 shares and 3,000 restricted stock units on February 18, 2026, both at a price of $0.00 per share.
The options vest in four equal annual installments beginning on February 18, 2027. Each restricted stock unit converts into one share of common stock and is settled in stock upon vesting, also in four equal annual installments starting on February 18, 2027. Following these grants, Mottola directly holds 15,724 shares of common stock, which include 228 shares acquired through the company’s employee stock purchase plan, along with the 13,500 options and 3,000 restricted stock units.